Antibody-drug conjugates (ADCs), a potent class of anticancer therapeutics, comprise a high-affinity antibody (Ab) and cytotoxic payload coupled via a suitable linker for selective tumor cell killing. In the initial phase of their development, two ADCs, Mylotarg®, and Adcetris® were approved by the US Food and Drug Administration (FDA) for treating hematological cancer, but the real breakthrough came with the discovery of the breast cancer-targeting ADC, Kadcyla®. With advances in bioengineering, linker chemistry, and potent cytotoxic payload, ADC technology has become a more powerful tool for targeted cancer therapy. In addition, ADCs with improved safety using humanized Abs with a unified 'drug:antibody ratio' (DAR) have been achieved. Concomitantly, there has been a significant increase in the number of clinical trials with anticancer ADCs with high translation potential.

中文翻译：

---

抗体-药物偶联物的进展：靶向癌症治疗的新时代。

抗体-药物偶联物（ADC）是一类有效的抗癌治疗药物，包含高亲和力抗体（Ab）和通过合适的接头偶联的细胞毒性有效载荷，以选择性杀伤肿瘤细胞。在开发的最初阶段，Mylotarg®和Adcetris®这两个ADC已获美国食品药品管理局（FDA）批准用于治疗血液学癌症，但真正的突破是针对乳腺癌的ADC的发现， Kadcyla®。随着生物工程，接头化学和有效的细胞毒性有效载荷的发展，ADC技术已成为靶向癌症治疗的更强大工具。此外，已经实现了使用具有统一“药物：抗体比率”（DAR）的人源化Abs改善了安全性的ADC。同时，